Buscar
Maze Therapeutics Inc
MAZEAñadir a la lista de seguimiento
24.580USD
-1.790-6.79%
Cierre 09-09 16:00（ET）
1.37BCap. mercado
PérdidaP/E TTM
Más Datos de Maze Therapeutics Inc Compañía
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Perfil de Maze Therapeutics Inc
Símbolo de cotizaciónMAZE
Nombre de la empresaMaze Therapeutics Inc
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoColoma (Jason V)
Número de empleados125
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección171 Oyster Point Boulevard, Suite 300
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16508505070
Sitio Webhttps://www.mazetx.com/
Símbolo de cotizaciónMAZE
Fecha de salida a bolsaJan 31, 2025
Director ejecutivoColoma (Jason V)
Ejecutivos de Maze Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
35.75K
+34.97%
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
20.00K
--
Ms. Amy Bachrodt
Ms. Amy Bachrodt
Investor Contact
Investor Contact
12.96K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
35.75K
+34.97%
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
20.00K
--
Ms. Amy Bachrodt
Ms. Amy Bachrodt
Investor Contact
Investor Contact
12.96K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Maze Therapeutics Inc?
Los cinco principales accionistas de Maze Therapeutics Inc son: Dr. Jonathan E. Lim, M.D.
¿Cuántas instituciones poseen acciones de Maze Therapeutics Inc (MAZE)?
A fecha de 2026Q1, 213 instituciones poseen acciones de Maze Therapeutics Inc, con un valor de mercado combinado de aproximadamente 53.41M, lo que representa el 97.33% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 12392855.00.